Analyst Ratings for [CROX] Crocs, Inc.

3/12/25	Upgrades	Hold Buy	X
CROX Crocs Loop Capital
$110
11/22/24	Initiated	Buy	X
CROX Crocs Needham
$116
11/7/24	Downgrades	Buy Hold	X
CROX Crocs Loop Capital
$150 $110
10/30/24	Reiterated	Buy	X
CROX Crocs Monness Crespi & Hardt
$170 $140
10/30/24	Downgrades	Outperform Mkt Perform	X
CROX Crocs Raymond James
10/9/24	Initiated	Buy	X
CROX Crocs Guggenheim
$182
8/23/24	Resumed	Overweight	X
CROX Crocs Piper Sandler
$170
5/8/24	Reiterated	Buy	X
CROX Crocs Monness Crespi & Hardt
$140 $170
4/1/24	Initiated	Overweight	X
CROX Crocs Barclays
$167
2/7/24	Initiated	Overweight	X
CROX Crocs KeyBanc Capital Markets
$130
12/12/23	Initiated	Buy	X
CROX Crocs BofA Securities
$128
11/28/23	Upgrades	Outperform Strong Buy	X
CROX Crocs Raymond James
$98 $115
10/20/23	Upgrades	Mkt Perform Outperform	X
CROX Crocs Raymond James
$110
9/7/23	Downgrades	Buy Neutral	X
CROX Crocs B. Riley Securities
$125 $101
7/28/23	Upgrades	Hold Buy	X
CROX Crocs Stifel
$140 $130
6/14/23	Initiated	Mkt Perform	X
CROX Crocs Raymond James
3/30/23	Initiated	Buy	X
CROX Crocs B. Riley Securities
$157
9/21/22	Initiated	Neutral	X
CROX Crocs Exane BNP Paribas
7/26/22	Resumed	Overweight	X
CROX Crocs Piper Sandler
$120 $90
7/5/22	Upgrades	Hold Buy	X
CROX Crocs Loop Capital
$75
4/29/22	Initiated	Outperform	X
CROX Crocs Wedbush
$90
1/18/22	Initiated	Neutral	X
CROX Crocs Seaport Research Partners
7/23/21	Reiterated	Buy	X
CROX Crocs B. Riley Securities
$132 $152
7/23/21	Reiterated	Buy	X
CROX Crocs Monness Crespi & Hardt
$125 $160
4/28/21	Reiterated	Buy	X
CROX Crocs Monness Crespi & Hardt
$91 $125
2/19/21	Reiterated	Buy	X
CROX Crocs Pivotal Research Group
$87 $92
1/13/21	Reiterated	Buy	X
CROX Crocs Monness Crespi & Hardt
$60 $91
1/12/21	Reiterated	Buy	X
CROX Crocs Pivotal Research Group
$68 $87
7/15/19	Upgrades	Neutral Overweight	X
CROX Crocs Piper Jaffray
$22 $27
6/27/19	Upgrades	Neutral Buy	X
CROX Crocs CL King
6/21/19	Upgrades	Neutral Outperform	X
CROX Crocs Robert W. Baird
$29
6/14/19	Reiterated	Neutral	X
CROX Crocs Piper Jaffray
$31 $22
4/23/19	Downgrades	Overweight Neutral	X
CROX Crocs Piper Jaffray
$31
2/28/19	Upgrades	Neutral Buy	X
CROX Crocs Monness Crespi & Hardt
$32
1/15/19	Reiterated	Buy	X
CROX Crocs Pivotal Research Group
$33 $35
1/2/19	Upgrades	Neutral Positive	X
CROX Crocs Susquehanna
11/12/18	Upgrades	Negative Neutral	X
CROX Crocs Susquehanna
11/9/18	Reiterated	Buy	X
CROX Crocs Pivotal Research Group
$25 $32
11/6/18	Reiterated	Buy	X
CROX Crocs Pivotal Research Group
$21 $25
7/25/18	Upgrades	Hold Buy	X
CROX Crocs Pivotal Research Group
$15 $21
5/9/18	Downgrades	Buy Hold	X
CROX Crocs Stifel
$16 $17
5/2/18	Reiterated	Hold	X
CROX Crocs Pivotal Research Group
$13 $14
4/16/18	Downgrades	Neutral Negative	X
CROX Crocs Susquehanna
3/1/18	Upgrades	Neutral Overweight	X
CROX Crocs Piper Jaffray

CROX Crocs, Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Crocs, Inc. is engaged in the design, development, manufacturing, marketing, distribution and sale of casual lifestyle footwear and accessories for men, women, and children. The Company's segments include Americas, Asia Pacific and Europe. Its products include footwear and accessories that utilize its closed-cell resin, called Croslite, as well as casual lifestyle footwear that use a range of materials. Its Croslite material enables the Company to produce non-marking, and odor-resistant footwear. As of December 31, 2016, the Company sold its products in over 90 countries through domestic and international retailers and distributors, and directly to consumers through its company-operated retail stores, outlets, e-commerce store sites and kiosks. The Company's sales channels include wholesale, which includes distributors, Crocs owned retail and Crocs e-commerce.